Psychotic disorders affect 3% of the population at some stage in life, are a leading cause of
disability, and impose a great economic burden on society. Major breakthroughs in the …

Focusing on biomarker identification and using biomarkers individually or in clusters to
define biological subgroups in psychiatry requires a re-orientation from behavioral …

The burden of large and rare copy number genetic variants (CNVs) as well as certain
specific CNVs increase the risk of developing schizophrenia. Several cognitive measures …

Social anxiety disorder (SAD) runs in families, but the neurobiological pathways underlying
the genetic susceptibility towards SAD are largely unknown. Here, we employed an …

BackgroundThe N100, an early auditory event-related potential, has been found to be
altered in patients with psychosis. However, it is unclear if the N100 is a psychosis …

BackgroundA wealth of clinical studies have identified objective biomarkers, which separate
schizophrenia patients from healthy controls on a group level, but current diagnostic systems …

Endophenotypes are mediator traits between genetic influences and clinical phenotypes.
Meta-analyses have consistently shown modest impairments of executive functioning in …

Schizophrenia (SCZ) is a severe psychotic disorder that affects up to 1% of the US
population and it is associated with progressive impairment in social functioning and …

Trait disinhibition may function as a dispositional liability toward maladaptive behaviors
relevant in the treatment of mentally disordered offenders (MDOs). Reduced amplitude and …

Social anxiety disorder (SAD) is serious psychiatric condition with a genetic background.
Insight into the neurobiological alterations underlying the disorder is essential to develop …